



Company Announcement no. 14/2009

To: NASDAQ OMX Copenhagen

Hørsholm, Denmark, August 12, 2009

### LifeCycle Pharma's Updated Financial Calendar 2009

LifeCycle Pharma A/S (OMX: LCP) issues today an updated financial calendar for 2009:

August 20, 2009: Interim Report for 2<sup>nd</sup> Quarter – for the period ending June 30, 2009.

(Changes from publication after end of business day on August 19, 2009 to the morning of August 20, 2009, 9:00 AM CET due to board travelling arrangements).

November 11, 2009: Interim Report for 3<sup>rd</sup> Quarter – for the period ending September 30, 2009 (unchanged).

#### For more information, please contact:

LifeCycle Pharma A/S

Dr. Jim New

President & CEO

+45 70 33 33 00; [jsn@lcpharma.com](mailto:jsn@lcpharma.com)

Peter Schøtt Knudsen

Head of Investor Relations

+45 20 55 38 17; [psk@lcpharma.com](mailto:psk@lcpharma.com)

#### About LifeCycle Pharma A/S (LCP)

*Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging specialty pharmaceutical company. Clinical development is the core of LCP's effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. As a fully integrated company, LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose<sup>®</sup>, can improve absorption and bioavailability – at low-scale up costs – not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a cholesterol-lowering product, Fenoglide<sup>™</sup>, currently on the U.S. market and a diversified near- and medium-term pipeline with four product candidates in clinical trials and a number of projects in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under the trading symbol (OMX: LCP).*

For further information, please visit [www.lcpharma.com](http://www.lcpharma.com).